Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Colorectal Cancer: Predicted 5-Year DFS with/without 5FU-Based Adjuvant Therapy

Predicted 5-Year DFS Estimates (%) by T stage, Nodal Status, and Grade for Patients Treated With Surgery Alone and Surgery With FU-Based Adjuvant Chemotherapy

A pooled analysis of adjuvant chemotherapy trials for patients with resected colon cancer was performed to quantify the benefit of 5FU-based chemotherapy for predefined clinical and pathologic subgroups. The table below provides individualised estimates of baseline prognosis and adjuvant-therapy benefit based on T stage, nodal status and grade.

Results are presented as % patients still alive at 5 years with 95% confidence interval and group size. 

Low grade patients

Group

Surgery Alone

Surgery + Chemotherapy

Abs. gain (%)

0 nodes & T1-2

N/A

N/A

0 nodes & T3

73 - [69 - 76]

77 - [74 - 80]

4

0 nodes & T4

60 - [54 - 68]

66 - [59 - 73]

6

1-4 nodes & T1-2

62 - [56 - 70]

75 - [70 - 81]

13

1-4 nodes & T3

49 - [45 - 54]

65 - [62 - 69]

16

1-4 nodes & T4

33 - [26 - 43]

51 - [44 - 60]

18

5+ nodes & T1-2

39 - [30 - 51]

57 - [48 - 67]

18

5+ nodes & T3

24 - [19 - 31]

43 - [37 - 49]

19

5+ nodes & T4

11 - [6 - 20]

27 - [19 - 37]

16

High grade patients

Group

Surgery Alone

Surgery + Chemotherapy

Abs. gain (%)

0 nodes & T1-2

N/A

N/A

0 nodes & T3

65 - [60 - 70]

70 - [65 - 74]

5

0 nodes & T4

51 - [43 - 60]

57 - [49 - 66]

6

1-4 nodes & T1-2

53 - [44 - 63]

68 - [61 - 76]

15

1-4 nodes & T3

38 - [33 - 44]

56 - [51 - 62]

18

1-4 nodes & T4

23 - [16 - 32]

40 - [32 - 51]

17

5+ nodes & T1-2

28 - [19 - 42]

46 - [37 - 58]

18

5+ nodes & T3

15 - [10 - 22]

32 - [26 - 39]

17

5+ nodes & T4

5 - [3 - 12]

17 - [11 - 26]

12

Abbreviations

  • DFS: disease-free survival
  • 5-FU: 5-fluorouracil
  • N/A: not applicable (because of insufficient clinical data for resected T1 to T2, N0 or stage I colon cancer)

Reprinted with permission. ©2008 American Society of Clinical Oncology. All rights reserved. Gill S et al: Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? J Clin Oncol Vol.22 (10), 2004: 1797-1806.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings